Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas

K Kohshi, Y Kinoshita, H Imada, N Kunugita, H Abe, H Terashima, N Tokui, S Uemura, K Kohshi, Y Kinoshita, H Imada, N Kunugita, H Abe, H Terashima, N Tokui, S Uemura

Abstract

The purpose of this non-randomized trial was to evaluate the efficacy of radiotherapy combined with hyperbaric oxygen (HBO) in patients with malignant glioma. Between 1987 and 1997, 29 patients in whom computerized tomography (CT) or magnetic resonance imaging (MRI) scans showed post-operative residual tumours were locally irradiated with nitrosourea-based chemotherapy. Treatments were consecutively combined with HBO at two institutions since 1991 and 1993. Fifteen patients were irradiated daily after HBO, and the periods of time from decompression to irradiation were within 15 and 30 min in 11 and four patients respectively. Fourteen other patients were treated without HBO. Tumour responses were assessed by CT or MRI scans and survival times were compared between the treated groups. In the HBO group, 11 of 15 patients (73%) showed > or = 50% tumour regression. All responders were irradiated within 15 min after decompression. In the non-HBO group, four of 14 patients (29%) showed tumour regression. The median survivals in patients with and without HBO were 24 and 12 months, respectively, and were significantly different (P < 0.05). No serious side-effects were observed in the HBO patients. In conclusion, irradiation after HBO seems to be a useful form of treatment for malignant gliomas, but irradiation should be administered immediately after decompression.

References

    1. J Natl Cancer Inst. 1993 May 5;85(9):704-10
    1. J Nucl Med. 1992 Dec;33(12):2133-7
    1. Nat Med. 1997 Feb;3(2):177-82
    1. Br J Cancer. 1997;75(3):311-8
    1. J Neurosurg. 1996 Mar;84(3):442-8
    1. Br J Cancer. 1995 Apr;71(4):721-6
    1. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):417-28
    1. Br J Radiol. 1989 Aug;62(740):679-94
    1. J Neurosurg. 1991 Jan;74(1):55-9
    1. Radiother Oncol. 1991;20 Suppl 1:71-4
    1. Br J Radiol. 1953 Dec;26(312):638-48
    1. Neuroradiology. 1982;23(2):63-74
    1. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1339-41
    1. Cancer. 1987 May 1;59(9):1617-25
    1. Cancer Res. 1988 May 15;48(10):2938-41
    1. Cancer. 1994 May 1;73(9):2386-94
    1. Clin Radiol. 1978 May;29(3):333-8
    1. Lancet. 1977 Jul 16;2(8029):101-3
    1. Cancer Chemother Rep. 1966 Mar;50(3):163-70
    1. J Neurosurg. 1994 Dec;81(6):902-9
    1. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279-82
    1. J Appl Physiol. 1963 Sep;18:869-76
    1. J Clin Oncol. 1988 Feb;6(2):338-43
    1. Natl Cancer Inst Monogr. 1977 Dec;46:163-9
    1. Br J Cancer. 1955 Dec;9(4):539-49
    1. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31
    1. J Nucl Med. 1987 Jul;28(7):1123-33
    1. J Neurosurg. 1986 Dec;65(6):799-806
    1. Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):903-5
    1. Clin Radiol. 1974 Apr;25(2):211-5
    1. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):125-30
    1. Br J Radiol. 1978 Nov;51(611):879-87
    1. J Nucl Med. 1993 Jun;34(6):885-8
    1. J Cancer Res Clin Oncol. 1996;122(11):676-8

Source: PubMed

3
Suscribir